Timrepigene emparvovec for choroideremia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 11 Dec 2017: Trial started, NCT03496012
  2. 12 Apr 2018: Trial registered, NCT03496012
  3. 4 Jun 2018: Trial started, NCT03584165
  4. 12 Jul 2018: Trial registered, NCT03584165

The trials

NCT02553135: Choroideremia Gene Therapy Clinical Trial

State
Completed
Phase
Phase 2
People
6 taking part
Started
Sep 2015
Primary completion
Feb 2018
Arms
Injection of AAV2-REP1
Results
Posted on the registry
  1. 17 Sep 2015: Trial registered
  2. 29 Jul 2019: Trial results posted

NCT03496012: Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

State
Completed
Phase
Phase 3
People
169 taking part
Started
11 Dec 2017
Primary completion
1 Dec 2020
Arms
BIIB111 High Dose, BIIB111 Low Dose
Results
Posted on the registry
  1. 11 Dec 2017: Trial started
  2. 12 Apr 2018: Trial registered
  3. 1 Dec 2020: Trial completed
  4. 7 Dec 2023: Trial results posted

NCT03507686: A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

State
Completed
Phase
Phase 2
People
66 taking part
Started
29 Nov 2017
Primary completion
29 Jun 2022
Arms
BIIB111
Results
Posted on the registry
  1. 29 Nov 2017: Trial started
  2. 25 Apr 2018: Trial registered
  3. 29 Jun 2022: Trial completed
  4. 18 Sep 2023: Trial results posted

NCT03584165: Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

State
Completed
Phase
Phase 3
People
277 taking part
Started
4 Jun 2018
Primary completion
22 Jun 2026
Arms
BIIB111
Results
None posted
  1. 4 Jun 2018: Trial started
  2. 12 Jul 2018: Trial registered
  3. 22 Jun 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as BIIB111, Injection of AAV2-REP1 (10e11 vg).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.